Dividends & Buybacks ·
QIAGEN N.V. held its Annual General Meeting on June 24, 2026, where shareholders approved a cash dividend of $0.35 per…
QGENQiagen N.V.
QIAGEN N.V. held its Annual General Meeting on June 24, 2026, where shareholders approved a cash dividend of $0.35 per ordinary share for 2026, totaling approximately $72 million gross. The meeting also authorized the Managing Board to implement a synthetic share repurchase program with a maximum aggregate repayment amount of $200 million. This mechanism involves increasing par value, consolidating shares via a reverse stock split ratio determined by management, and reducing par value to repay capital. Additionally, shareholders reappointed eight Supervisory Directors including new member Robert McMahon, reappointed Managing Directors Thierry Bernard and Roland Sackers, approved an amendment to the executive remuneration policy, and renewed share repurchase authorizations up to 10% of issued capital. QIAGEN N.V. operates in the life sciences industry, providing sample-to-insight molecular diagnostics solutions.